Astrocyteendothelial interactions at the bloodbrain barrier
but the reduction in fasting plasma glucose was relatively small [1]
Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
Furthermore, liraglutide, subcutaneous semaglutide, and tirzepatide are approved for chronic weight management regardless of diabetes status